inositol has been researched along with Cognition Disorders in 52 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to test whether in vivo levels of magnetic resonance spectroscopy (MRS) metabolites myo-inositol (mI), N-acetylaspartate (NAA), and choline are abnormal already during preclinical Alzheimer disease (AD), relating these changes to amyloid or tau pathology, and functional connectivity." | 7.83 | Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease. ( Blennow, K; Hansson, O; Minthon, L; Strandberg, O; Sundgren, PC; Voevodskaya, O; Wahlund, LO; Westman, E; Zetterberg, H, 2016) |
| "We aimed to test whether in vivo levels of magnetic resonance spectroscopy (MRS) metabolites myo-inositol (mI), N-acetylaspartate (NAA), and choline are abnormal already during preclinical Alzheimer disease (AD), relating these changes to amyloid or tau pathology, and functional connectivity." | 3.83 | Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease. ( Blennow, K; Hansson, O; Minthon, L; Strandberg, O; Sundgren, PC; Voevodskaya, O; Wahlund, LO; Westman, E; Zetterberg, H, 2016) |
| "目的：应用磁共振氢质子波谱(1H-proton magnetic resonance spectroscopy，1H-MRS)检测合并认知功能障碍的多系统萎缩(multiple system atrophy，MSA)患者双侧额叶的代谢特点。方法：收集23例合并认知功能障碍的MSA患者(研究组1)及19例认知功能正常的MSA患者(研究组2)，另选48名与两组MSA患者年龄、性别匹配的正常人(正常对照组)均进行1H-MRS检查，其包括双侧额叶区N-乙酰天门冬氨酸(N-acetylaspartate，NAA)/肌酸(creatine，Cr)、胆碱(choline，Cho)/肌酸(Cr)、肌醇(myoinositol，mI)/肌酸(Cr)的测定。结果：合并认知障碍的MSA患者双侧额叶NAA/Cr值较认知正常的MSA患者和正常对照组显著降低(P<0." | 3.81 | [1H-proton magnetic resonance spectroscopy in patients with multiple system atrophy and cognitive dysfunction]. ( Hou, X; Jiang, H; Sun, Z; Tang, B; Xiang, X; Zhou, G, 2015) |
| "Asymmetric dimethylarginine (ADMA) is an inhibitor of nitric oxide synthase that accumulates in liver disease and may contribute to hepatic encephalopathy (HE)." | 3.79 | Asymmetric dimethylarginine is strongly associated with cognitive dysfunction and brain MR spectroscopic abnormalities in cirrhosis. ( Ahluwalia, V; Bajaj, JS; Bouneva, I; Fuchs, M; Gilles, H; Heuman, DM; Kraft, KA; Luketic, V; Monteith, P; Noble, NA; Puri, P; Sanyal, AJ; Sterling, RK; Stravitz, RT; Wade, JB; White, MB, 2013) |
| "Glutamate plus glutamine was positively correlated with overall cognitive performance in the schizophrenia group (p = ." | 3.77 | Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. ( Apfeldorf, W; Bustillo, JR; Caprihan, A; Chen, H; Gasparovic, C; Lauriello, J; Mullins, P; Posse, S; Qualls, C, 2011) |
| "Dementia was an independent predictor of metabolite values." | 2.73 | Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey. ( Antúnez, C; Carles, R; Fortuna, L; García Santos, JM; Gavrila, D; Jiménez Veiga, J; Navarro, C; Parrilla, G; Salmerón, D; Tormo, MJ; Torres del Río, S, 2008) |
| "Human hepatic encephalopathy (HE) is identified by a new noninvasive test, proton magnetic resonance spectroscopy (1H MRS) applied to the brain in a few minutes." | 2.39 | Proton magnetic resonance spectroscopy: the new gold standard for diagnosis of clinical and subclinical hepatic encephalopathy? ( Blüml, S; Danielsen, ER; Ross, BD, 1996) |
| "Hyponatremia has a complex, non-linear relationship with brain Glx and mI, cognition and HRQOL." | 1.39 | Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis. ( Ahluwalia, V; Bajaj, JS; Bouneva, I; Fuchs, M; Gilles, H; Heuman, DM; Kraft, KA; Luketic, V; Puri, P; Sanyal, AJ; Sterling, RK; Stravitz, RT; Thacker, L; Wade, JB, 2013) |
| "The cognitive decline in Alzheimer's disease (AD) patients has been reported to involve alterations in the medial temporal lobe and the posterior cingulate gyrus." | 1.34 | A decrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimer's disease. ( Horiguchi, J; Inagaki, T; Inami, Y; Kawamukai, T; Miyaoka, T; Okazaki, S; Shinno, H; Utani, E, 2007) |
| "Given the available therapies for Alzheimer's disease, early diagnosis is of paramount importance." | 1.33 | Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. ( Fayed, N; Modrego, PJ; Pina, MA, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.92) | 18.7374 |
| 1990's | 2 (3.85) | 18.2507 |
| 2000's | 25 (48.08) | 29.6817 |
| 2010's | 24 (46.15) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rafii, MS | 1 |
| Skotko, BG | 1 |
| McDonough, ME | 1 |
| Pulsifer, M | 1 |
| Evans, C | 1 |
| Doran, E | 1 |
| Muranevici, G | 1 |
| Kesslak, P | 1 |
| Abushakra, S | 1 |
| Lott, IT | 1 |
| Ahluwalia, V | 2 |
| Wade, JB | 2 |
| Thacker, L | 1 |
| Kraft, KA | 2 |
| Sterling, RK | 2 |
| Stravitz, RT | 2 |
| Fuchs, M | 2 |
| Bouneva, I | 2 |
| Puri, P | 2 |
| Luketic, V | 2 |
| Sanyal, AJ | 2 |
| Gilles, H | 2 |
| Heuman, DM | 2 |
| Bajaj, JS | 2 |
| Ge, X | 1 |
| Xu, XY | 1 |
| Feng, CH | 1 |
| Wang, Y | 1 |
| Li, YL | 1 |
| Feng, B | 1 |
| Kolisnyk, B | 1 |
| Al-Onaizi, MA | 1 |
| Hirata, PH | 1 |
| Guzman, MS | 1 |
| Nikolova, S | 1 |
| Barbash, S | 1 |
| Soreq, H | 1 |
| Bartha, R | 1 |
| Prado, MA | 1 |
| Prado, VF | 1 |
| Bolognin, S | 1 |
| Buffelli, M | 1 |
| Puoliväli, J | 1 |
| Iqbal, K | 1 |
| Chang, L | 1 |
| Jiang, C | 1 |
| Cunningham, E | 1 |
| Buchthal, S | 1 |
| Douet, V | 1 |
| Andres, M | 1 |
| Ernst, T | 1 |
| Rammes, G | 1 |
| Gravius, A | 1 |
| Ruitenberg, M | 1 |
| Wegener, N | 1 |
| Chambon, C | 1 |
| Sroka-Saidi, K | 1 |
| Jeggo, R | 1 |
| Staniaszek, L | 1 |
| Spanswick, D | 1 |
| O'Hare, E | 1 |
| Palmer, P | 1 |
| Kim, EM | 1 |
| Bywalez, W | 1 |
| Egger, V | 1 |
| Parsons, CG | 1 |
| Kaufman, MJ | 1 |
| Janes, AC | 1 |
| Hudson, JI | 1 |
| Brennan, BP | 1 |
| Kanayama, G | 1 |
| Kerrigan, AR | 1 |
| Jensen, JE | 1 |
| Pope, HG | 1 |
| Xiang, X | 1 |
| Hou, X | 1 |
| Sun, Z | 1 |
| Zhou, G | 1 |
| Tang, B | 1 |
| Jiang, H | 1 |
| Yadav, SK | 1 |
| Gupta, RK | 1 |
| Saraswat, VA | 1 |
| Rangan, M | 1 |
| Thomas, MA | 1 |
| Rutella, S | 1 |
| Danese, S | 1 |
| Wang, E | 1 |
| Marincola, FM | 1 |
| Haris, M | 1 |
| Guo, Z | 1 |
| Zhang, J | 1 |
| Liu, X | 1 |
| Hou, H | 1 |
| Cao, Y | 1 |
| Wei, F | 1 |
| Li, J | 1 |
| Chen, X | 1 |
| Shen, Y | 1 |
| Chen, W | 1 |
| Maeba, R | 1 |
| Araki, A | 1 |
| Ishii, K | 1 |
| Ogawa, K | 1 |
| Tamura, Y | 1 |
| Yasunaga, M | 1 |
| Minami, U | 1 |
| Komori, A | 1 |
| Okazaki, T | 1 |
| Nishimukai, M | 1 |
| Hara, H | 1 |
| Fujiwara, Y | 1 |
| Van Dalen, YW | 1 |
| Blokhuis, C | 1 |
| Cohen, S | 1 |
| Ter Stege, JA | 1 |
| Teunissen, CE | 1 |
| Kuhle, J | 1 |
| Kootstra, NA | 1 |
| Scherpbier, HJ | 1 |
| Kuijpers, TW | 1 |
| Reiss, P | 1 |
| Majoie, CBLM | 1 |
| Caan, MWA | 1 |
| Pajkrt, D | 1 |
| Voevodskaya, O | 1 |
| Sundgren, PC | 1 |
| Strandberg, O | 1 |
| Zetterberg, H | 1 |
| Minthon, L | 1 |
| Blennow, K | 1 |
| Wahlund, LO | 1 |
| Westman, E | 1 |
| Hansson, O | 1 |
| García Santos, JM | 1 |
| Gavrila, D | 1 |
| Antúnez, C | 1 |
| Tormo, MJ | 1 |
| Salmerón, D | 1 |
| Carles, R | 1 |
| Jiménez Veiga, J | 1 |
| Parrilla, G | 1 |
| Torres del Río, S | 1 |
| Fortuna, L | 1 |
| Navarro, C | 1 |
| Erichsen, AK | 1 |
| Server, A | 1 |
| Landrø, NI | 1 |
| Sandvik, L | 1 |
| Tallaksen, CM | 1 |
| Haroon, E | 1 |
| Watari, K | 1 |
| Thomas, A | 1 |
| Ajilore, O | 1 |
| Mintz, J | 1 |
| Elderkin-Thompson, V | 1 |
| Darwin, C | 1 |
| Kumaran, S | 1 |
| Kumar, A | 1 |
| Wang, Z | 1 |
| Zhao, C | 1 |
| Yu, L | 1 |
| Zhou, W | 1 |
| Li, K | 1 |
| Pilatus, U | 1 |
| Lais, C | 1 |
| Rochmont, Adu M | 1 |
| Kratzsch, T | 1 |
| Frölich, L | 1 |
| Maurer, K | 1 |
| Zanella, FE | 1 |
| Lanfermann, H | 2 |
| Pantel, J | 1 |
| Winston, A | 1 |
| Garvey, L | 1 |
| Scotney, E | 1 |
| Yerrakalva, D | 1 |
| Allsop, JM | 1 |
| Thomson, EC | 1 |
| Grover, VP | 1 |
| Main, J | 1 |
| Cox, JI | 1 |
| Wylezinska, M | 1 |
| Taylor-Robinson, SD | 1 |
| Griffith, HR | 3 |
| Okonkwo, OC | 1 |
| den Hollander, JA | 2 |
| Belue, K | 1 |
| Copeland, J | 1 |
| Harrell, LE | 3 |
| Brockington, JC | 3 |
| Clark, DG | 1 |
| Marson, DC | 3 |
| Bokemeyer, M | 1 |
| Ding, XQ | 1 |
| Goldbecker, A | 1 |
| Raab, P | 1 |
| Heeren, M | 1 |
| Arvanitis, D | 1 |
| Tillmann, HL | 1 |
| Weissenborn, K | 1 |
| Bustillo, JR | 1 |
| Chen, H | 1 |
| Gasparovic, C | 1 |
| Mullins, P | 1 |
| Caprihan, A | 1 |
| Qualls, C | 1 |
| Apfeldorf, W | 1 |
| Lauriello, J | 1 |
| Posse, S | 1 |
| Haley, AP | 2 |
| Gonzales, MM | 2 |
| Tarumi, T | 2 |
| Miles, SC | 1 |
| Goudarzi, K | 1 |
| Tanaka, H | 2 |
| Hancu, I | 1 |
| Gillen, R | 1 |
| Cowan, J | 1 |
| Zimmerman, EA | 1 |
| Byrnes, V | 1 |
| Miller, A | 1 |
| Lowry, D | 1 |
| Hill, E | 1 |
| Weinstein, C | 1 |
| Alsop, D | 1 |
| Lenkinski, R | 1 |
| Afdhal, NH | 1 |
| Lim, TS | 1 |
| Hong, YH | 1 |
| Lee, HY | 1 |
| Choi, JY | 1 |
| Kim, HS | 1 |
| Moon, SY | 1 |
| Eagan, DE | 1 |
| Vaghasia, M | 1 |
| White, MB | 1 |
| Noble, NA | 1 |
| Monteith, P | 1 |
| Pies, R | 1 |
| Weiss, U | 1 |
| Bacher, R | 1 |
| Vonbank, H | 1 |
| Kemmler, G | 1 |
| Lingg, A | 1 |
| Marksteiner, J | 1 |
| Gonen, O | 1 |
| Kantarci, K | 2 |
| Reynolds, G | 1 |
| Petersen, RC | 2 |
| Boeve, BF | 2 |
| Knopman, DS | 1 |
| Edland, SD | 1 |
| Smith, GE | 2 |
| Ivnik, RJ | 2 |
| Tangalos, EG | 2 |
| Jack, CR | 2 |
| Waldman, AD | 1 |
| Rai, GS | 1 |
| Frederick, BD | 1 |
| Lyoo, IK | 1 |
| Satlin, A | 1 |
| Ahn, KH | 1 |
| Kim, MJ | 1 |
| Yurgelun-Todd, DA | 1 |
| Cohen, BM | 1 |
| Renshaw, PF | 1 |
| Wang, LN | 1 |
| Wang, W | 1 |
| Zhang, XH | 1 |
| Ma, L | 1 |
| Yin, H | 1 |
| Li, DJ | 1 |
| Modrego, PJ | 1 |
| Fayed, N | 1 |
| Pina, MA | 1 |
| Metastasio, A | 1 |
| Rinaldi, P | 1 |
| Tarducci, R | 2 |
| Mariani, E | 1 |
| Feliziani, FT | 1 |
| Cherubini, A | 2 |
| Pelliccioli, GP | 2 |
| Gobbi, G | 2 |
| Senin, U | 2 |
| Mecocci, P | 2 |
| Azevedo, D | 1 |
| Bottino, CM | 1 |
| Tatsch, M | 1 |
| Hototian, SR | 1 |
| Bazzarella, MC | 1 |
| Castro, CC | 1 |
| Stewart, CC | 1 |
| Evanochko, WT | 2 |
| Buchthal, SD | 1 |
| Zamrini, EY | 2 |
| Shinno, H | 1 |
| Inagaki, T | 1 |
| Miyaoka, T | 1 |
| Okazaki, S | 1 |
| Kawamukai, T | 1 |
| Utani, E | 1 |
| Inami, Y | 1 |
| Horiguchi, J | 1 |
| Hollander, JA | 1 |
| Okonkwo, O | 1 |
| Rami, L | 1 |
| Gómez-Ansón, B | 1 |
| Bosch, B | 1 |
| Sánchez-Valle, R | 1 |
| Monte, GC | 1 |
| Villar, A | 1 |
| Molinuevo, JL | 1 |
| Gropman, AL | 1 |
| Seltzer, RR | 1 |
| Yudkoff, M | 1 |
| Sawyer, A | 1 |
| VanMeter, J | 1 |
| Fricke, ST | 1 |
| Summers, M | 1 |
| Swanton, J | 1 |
| Fernando, K | 1 |
| Dalton, C | 1 |
| Miller, DH | 1 |
| Cipolotti, L | 1 |
| Ron, MA | 1 |
| Ross, BD | 1 |
| Danielsen, ER | 1 |
| Blüml, S | 1 |
| Salvan, AM | 1 |
| Ceccaldi, M | 1 |
| Confort-Gouny, S | 1 |
| Milandre, C | 1 |
| Cozzone, PJ | 1 |
| Vion-Dury, J | 1 |
| Xu, YC | 1 |
| Campeau, NG | 1 |
| O'Brien, PC | 1 |
| Kokmen, E | 1 |
| Brooks, WM | 1 |
| Stidley, CA | 1 |
| Petropoulos, H | 1 |
| Jung, RE | 1 |
| Weers, DC | 1 |
| Friedman, SD | 1 |
| Barlow, MA | 1 |
| Sibbitt, WL | 1 |
| Yeo, RA | 1 |
| Malloy, CR | 1 |
| Catani, M | 1 |
| Howard, R | 1 |
| Piccirilli, M | 1 |
| Lepkifker, E | 1 |
| Lewin, LM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 4-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2a Safety and PK Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia[NCT01791725] | Phase 2 | 23 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| The Swedish BioFINDER Study: Early Diagnosis of Alzheimer's Disease - a Multidisciplinary Approach[NCT01208675] | 1,150 participants (Actual) | Observational | 2010-09-30 | Active, not recruiting | |||
| Personalized Medicine in HCV Infection: Cognitive Impairments and Brain Anomalies in Chronic Hepatitis C Infected Individuals. Characterization and Potential Reversibility With Direct Antiviral Agents.[NCT02745132] | Phase 4 | 80 participants (Anticipated) | Interventional | 2016-06-30 | Not yet recruiting | ||
| A Study of the Cerebral Effect of Pegylated Interferon in Hepatitis C Positive Subjects[NCT00136214] | 22 participants (Actual) | Observational | 2004-03-31 | Completed | |||
| In Vivo Investigation on Mitochondrial Dysfunction in Post-COVID Fatigue and Cancer Fatigue.[NCT05753228] | 90 participants (Anticipated) | Interventional | 2022-12-09 | Recruiting | |||
| An Open-label Exploratory Study With Memantine: Correlation Between Proton Magnetic Resonance Spectroscopy, Cerebrospinal Fluid Biomarkers, and Cognition in Patients With Mild to Moderate Alzheimer's Disease[NCT00551161] | Phase 4 | 12 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Neuropsychiatric Inventory(NPI) (Cummings et al 1994) is a behavioral measure that assesses psychopathology in dementia patients. The NPI was administered at the Baseline Visit (Day 1) and at Day 28 (EOS) or ET. A decrease in score shows an improvement in symptoms. (NCT01791725)
Timeframe: Baseline and 4 weeks
| Intervention | participants (Number) |
|---|---|
| ELND005 BID | 7 |
| ELND005 QD | 0 |
| Placebo | 1 |
For all AE summaries, if a patient had more than one AE within a preferred term, the patient was counted only once, at the maximum severity and with the closest relationship to study drug. If a patient had more than one AE within a SOC, the subject was similarly counted only once when reporting results for that SOC. (NCT01791725)
Timeframe: 4 weeks
| Intervention | participants (Number) |
|---|---|
| ELND005 BID | 5 |
| ELND005 QD | 2 |
| Placebo | 0 |
Subjects with Abnormal Neurological Examination Results (NCT01791725)
Timeframe: Baseline and 4 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Baseline | Week 4 | |
| ELND005 BID | 4 | 4 |
| ELND005 QD | 1 | 1 |
| Placebo | 3 | 3 |
Rapid Assessment for Development Disabilities (RADD) The RADD test was developed from the low-difficulty items from published intelligence tests (Walsh et al 2007). It was specifically developed for evaluation of individuals with intellectual disabilities and developmental disabilities. It is a validated and reliable cognitive screening instrument that can be rapidly administered. The RADD is composed of 76 items. Each item is scored as 0 (incorrect) or 1 (correct).The test assesses a wide range of functional abilities including receptive and expressive language, orientation, registration, recall, attention, self identification, motor skills, imitation, abstract reasoning, number skills, comprehension and short-term memory to give a total score. Scores are from 0 to 76. A higher total score is correlated with a higher Cognitive Impairment level. (NCT01791725)
Timeframe: Baseline and 4 Weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Day 0 | Week 4 | |
| ELND005 BID | 58.7 | 59.1 |
| ELND005 QD | 58.0 | 64.3 |
| Placebo | 62.2 | 62.8 |
Mean Plasma ELND005 Concentrations- Cmax (NCT01791725)
Timeframe: Baseline and 4 Weeks
| Intervention | μg/mL (Mean) | |
|---|---|---|
| Mean Cmax, First Dose, Day 0 | Mean Cmax, Last Dose, Day 28 | |
| ELND005 BID | 1.68 | 6.33 |
| ELND005 QD | 2.61 | 4.48 |
| Placebo | 0 | 0 |
A battery of pen and paper neurocognitive tests where subject means are reported compared to the normative Z score. Data is reported at baseline (T1), week 12 on treatment (T2) and 12 weeks after treatment (week 60, T3). Improvements are increases in the test result compared to baseline as determined against the Z score. tests performed included Hopkins learning trials (HVLT), a measure of of verbal learning and memory and the Roy-Osterrieth Complex figure test (ROCF) which evaluates visio-spatal abilities, memory, planning and working memory. Improvements in the score (increases in value compared, either less negative or more positive to the Z score) shown in the table are reflective of improvements in these neurocognitive parameters. (NCT00136214)
Timeframe: 18 months overall with measures performed at baseline (T1), week 12 (T2) and 12 weeks after end of treatment (T3) with PEG-IFN for 48 weeks which is 60 weeks post baseline and only done in treated group and not controls
| Intervention | Z-score (Mean) | |||||
|---|---|---|---|---|---|---|
| HVLT, Verbal Learning Total, T1 | HVLT, Verbal Learning Total, T2 | HVLT, Verbal Learning Total, T3 | ROCF, T1 | ROCF, T2 | ROCF,T3 | |
| Interferon Treated Group | -1.43 | -0.78 | -0.7 | 0.34 | 0.15 | 0.33 |
| Non-treated Cohort Control | -2.0 | -1.16 | NA | -1.0 | 0.05 | NA |
Evaluation of changes in MR spectroscopy. reductions in ratio of Cho and MI reflect improvements in cerebral inflammation and improvement in cognition. Increases in the NAA ratio are suggestive of improvement in cognitive function. (NCT00136214)
Timeframe: 18 months overall with measures performed at baseline (T1), week 12 (T2) and 12 weeks after end of treatment (T3) with PEG-IFN for 48 weeks which is 60 weeks post baseline
| Intervention | ratio (Mean) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Basal Ganglia, T1, Cho/Cr | Basal Ganglia,T2, Cho/Cr | Basal Ganglia, T3, Cho/Cr | Basal Ganglia, T1, MI/Cr | Basal Ganglia T2. MI/C | Basal Ganglia T3, MI/C | Frontal Cortex T1, Cho/Cr | Frontal Cortex T2, Cho/Cr | Frontal Cortex T3, Cho/Cr | Basal Ganglia T1, NAA/Cr | Basal Ganglia T2, NAA/Cr | Basal Ganglia T3, NAA/Cr | Frontal Cortex T1,Mi/Cr | Frontal Cortex T2, MI/Cr | Frontal Cortex T3, MI/Cr | Frontal Cortex T1, NAA/Cr | Frontal Cortex T2, NAA/Cr | Frontal Cortex T3, NAA/Cr | DLPFC T1, Cho/Cr | DLPFC T2, Cho/Cr | DLPFC T3, Cho/Cr | DLPFC T1, MI/Cr | DLPFC T2, MI/Cr | DLPFC T3/ MI/Cr | DLPFC T1, NAA/Cr | DLPFC T2, NAA/Cr | DLFPC T3, NAA/Cr | |
| Interferon Treated Group | 0.42 | 0.28 | 0.34 | 0.78 | 0.71 | 0.75 | 0.29 | 0.26 | 0.29 | 1.26 | 1.25 | 1.09 | 0.68 | 0.75 | 0.71 | 1.73 | 1.74 | 1.75 | 0.31 | 0.25 | 0.26 | 0.79 | 0.75 | 0.93 | 1.72 | 1.65 | 1.78 |
| Non-treated Cohort Control | 0.30 | 0.28 | NA | 0.78 | 0.72 | NA | 0.28 | 0.29 | NA | 1.28 | 1.07 | NA | 0.77 | 1.19 | NA | 1.55 | 1.72 | NA | 0.27 | 0.27 | NA | 0.78 | 0.86 | NA | 1.61 | 1.60 | NA |
Ratios of myo-inositol (mI), N-acetylaspartate (NAA), total creatine (Cr), and choline (Cho) by single voxel 1H MRS (proton magnetic resonance spectroscopy). Mean (± SD) metabolite levels (normalized to T2-corrected water signal intensity) and metabolite ratios for Alzheimer's disease subjects at baseline (t0), after 24 weeks of ongoing monotherapy with stable-dose cholinesterase inhibitor (t1), and after another 24 weeks of combination therapy with memantine in addition to stable-dose cholinesterase inhibitor (t2). The Wilcoxon signed-rank test was used to examine whether the change between t0 and t1 differed from the change between t1 and t2 [(t2 - t1) - (t1 - t0)]. (NCT00551161)
Timeframe: Baseline, 24 weeks, and 48 weeks
| Intervention | ratio (normalized to T2-corrected water (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change in NAA [(t2-t1) - (t1-t0)] | Change in Cr [(t2-t1) - (t1-t0)] | Change in Cho [(t2-t1) - (t1-t0)] | Change in mI [(t2-t1) - (t1-t0)] | Change in NAA/Cr [(t2-t1) - (t1-t0)] | Change in Cho/Cr [(t2-t1) - (t1-t0)] | Change in mI/Cr [(t2-t1) - (t1-t0)] | Change in NAA/Cho [(t2-t1) - (t1-t0)] | Change in NAA/mI [(t2-t1) - (t1-t0)] | |
| Memantine | -54 | -2 | 9 | 16 | -0.09 | 0.02 | 0.04 | -0.26 | -0.35 |
1 review available for inositol and Cognition Disorders
| Article | Year |
|---|---|
Proton magnetic resonance spectroscopy: the new gold standard for diagnosis of clinical and subclinical hepatic encephalopathy?
Topics: Animals; Astrocytes; Brain; Choline; Cognition Disorders; Disease Models, Animal; Glutamine; Hepatic | 1996 |
3 trials available for inositol and Cognition Disorders
| Article | Year |
|---|---|
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (scyllo-Inositol) in Young Adults with Down Syndrome without Dementia.
Topics: Administration, Oral; Adolescent; Adult; Cognition Disorders; Double-Blind Method; Down Syndrome; El | 2017 |
Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition Disorders; Crea | 2008 |
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
Topics: Adult; Aged; Antiviral Agents; Aspartic Acid; Basal Ganglia; Choline; Cognition; Cognition Disorders | 2012 |
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
Topics: Adult; Aged; Antiviral Agents; Aspartic Acid; Basal Ganglia; Choline; Cognition; Cognition Disorders | 2012 |
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
Topics: Adult; Aged; Antiviral Agents; Aspartic Acid; Basal Ganglia; Choline; Cognition; Cognition Disorders | 2012 |
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
Topics: Adult; Aged; Antiviral Agents; Aspartic Acid; Basal Ganglia; Choline; Cognition; Cognition Disorders | 2012 |
48 other studies available for inositol and Cognition Disorders
| Article | Year |
|---|---|
Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis.
Topics: Brain; Cognition; Cognition Disorders; Diuretics; Female; Glutamic Acid; Glutamine; Hepatic Encephal | 2013 |
Relationships among serum C-reactive protein, receptor for advanced glycation products, metabolic dysfunction, and cognitive impairments.
Topics: Adult; Aged; Aspartic Acid; C-Reactive Protein; Cholesterol; Choline; Cognition Disorders; Female; H | 2013 |
Forebrain deletion of the vesicular acetylcholine transporter results in deficits in executive function, metabolic, and RNA splicing abnormalities in the prefrontal cortex.
Topics: Acetylcholine; Animals; Aspartic Acid; Choice Behavior; Choline; Cholinesterase Inhibitors; Cognitio | 2013 |
Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound.
Topics: Administration, Oral; Aging; Alzheimer Disease; Animals; Ciliary Neurotrophic Factor; Cognition Diso | 2014 |
Effects of APOE ε4, age, and HIV on glial metabolites and cognitive deficits.
Topics: Adult; Aging; Apolipoprotein E4; Choline; Cognition Disorders; Cross-Sectional Studies; Female; Fron | 2014 |
MRZ-99030 - A novel modulator of Aβ aggregation: II - Reversal of Aβ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice.
Topics: Amyloid beta-Peptides; Animals; Calcium; Cognition Disorders; Conditioning, Operant; Culture Media, | 2015 |
Brain and cognition abnormalities in long-term anabolic-androgenic steroid users.
Topics: Adult; Amygdala; Anabolic Agents; Androgens; Brain; Case-Control Studies; Cognition Disorders; Gluta | 2015 |
[1H-proton magnetic resonance spectroscopy in patients with multiple system atrophy and
cognitive dysfunction].
Topics: Aspartic Acid; Choline; Cognition Disorders; Creatine; Frontal Lobe; Humans; Inositol; Multiple Syst | 2015 |
Reduced cortical thickness in patients with acute-on-chronic liver failure due to non-alcoholic etiology.
Topics: Acute-On-Chronic Liver Failure; Adult; Aspartic Acid; Brain; Case-Control Studies; Cognition; Cognit | 2015 |
Neurometabolic characteristics in the anterior cingulate gyrus of Alzheimer's disease patients with depression: a (1)H magnetic resonance spectroscopy study.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Cognition Disorders; Creatine; Depressive Disorder; Female; | 2015 |
Serum ethanolamine plasmalogens improve detection of cognitive impairment among elderly with high excretion levels of urinary myo-inositol: A cross-sectional study.
Topics: Aged; Aged, 80 and over; Cognition Disorders; Cross-Sectional Studies; Female; Humans; Inositol; Mal | 2016 |
Neurometabolite Alterations Associated With Cognitive Performance in Perinatally HIV-Infected Children.
Topics: Adolescent; AIDS Dementia Complex; Aspartic Acid; Brain; CD4 Lymphocyte Count; Child; Choline; Cogni | 2016 |
Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Amyloidogenic Proteins; Apolipoprotein E4; Aspartic Acid; Brain; Brain Mapp | 2016 |
Proton magnetic resonance spectroscopy and cognition in patients with spastin mutations.
Topics: Adenosine Triphosphatases; Adult; Aspartic Acid; Biomarkers; Choline; Cognition Disorders; Creatine; | 2009 |
Prefrontal myo-inositol concentration and visuospatial functioning among diabetic depressed patients.
Topics: Aged; Cognition Disorders; Depressive Disorder, Major; Diabetes Mellitus, Type 2; Female; Humans; In | 2009 |
Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Cognition Disorders; Creatine; Dominance, | 2009 |
Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition; Cognition Disorders; Creatine; De | 2009 |
Does acute hepatitis C infection affect the central nervous system in HIV-1 infected individuals?
Topics: Adult; Basal Ganglia; Brain; Central Nervous System Diseases; Cognition Disorders; Creatinine; Hepat | 2010 |
Brain metabolic correlates of decision making in amnestic mild cognitive impairment.
Topics: Aged; Amnesia; Aspartic Acid; Brain; Choline; Cognition Disorders; Creatine; Decision Making; Female | 2010 |
Evidence for neuroinflammation and neuroprotection in HCV infection-associated encephalopathy.
Topics: Adult; Aged; Aspartic Acid; Brain; Brain Mapping; Case-Control Studies; Choline; Cognition Disorders | 2011 |
Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla.
Topics: Adult; Age Factors; Aspartic Acid; Biomarkers; Brain; Cognition Disorders; Female; Glutamic Acid; Gl | 2011 |
Elevated cerebral glutamate and myo-inositol levels in cognitively normal middle-aged adults with metabolic syndrome.
Topics: Adult; Brain Chemistry; Cognition Disorders; Disease Progression; Female; Glutamic Acid; Humans; Ino | 2010 |
Improved myo-inositol detection through Carr-Purcell PRESS: a tool for more sensitive mild cognitive impairment diagnosis.
Topics: Aged; Analysis of Variance; Aspartic Acid; Case-Control Studies; Cognition Disorders; Discriminant A | 2011 |
Metabolite investigation in both anterior and posterior cingulate gyri in Alzheimer's disease spectrum using 3-tesla MR spectroscopy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Cognition Disorders; Creatine; Disease Pr | 2012 |
Indirect effects of elevated body mass index on memory performance through altered cerebral metabolite concentrations.
Topics: Adult; Aspartic Acid; Biomarkers; Body Mass Index; Brain; Choline; Cognition Disorders; Creatine; Fe | 2012 |
Asymmetric dimethylarginine is strongly associated with cognitive dysfunction and brain MR spectroscopic abnormalities in cirrhosis.
Topics: Adult; Arginine; Aspartic Acid; Biomarkers; Brain; Cognition Disorders; Cross-Sectional Studies; Fem | 2013 |
The role of micronutrients as possible mood-stabilizing agents.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Child; Chromium; Cognition Disorders; Dietary Supple | 2002 |
Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Chemistry; Choline; Cognition Disorders; Creati | 2003 |
Higher field strength for proton MR spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Cognition Disorders; Creatinine; Humans; Inositol; Ma | 2003 |
Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition Disorders; Crea | 2003 |
The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Cognition Disorders; Creatinine; Dementia, Vascular | 2003 |
In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain Mapping; Case | 2004 |
[An interventional study on amnestic mild cognitive impairment with small dose donepezil].
Topics: Aged; Aged, 80 and over; Amnesia; Aspartic Acid; Cognition; Cognition Disorders; Creatine; Donepezil | 2004 |
Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition Disorders; Cohort Studies; Creatin | 2005 |
Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy.
Topics: Aged; Amnesia; Aspartic Acid; Cerebral Cortex; Choline; Cognition Disorders; Creatine; Dementia; Dis | 2006 |
[Proton spectroscopy in Alzheimer's disease and cognitive impairment not dementia: a community study].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Case-Control Studies; Choline; Cognition | 2005 |
Elevated brain scyllo-inositol concentrations in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Biopsy; Brain; Cognition Disorders; Creatine; Female; Humans | 2007 |
A decrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Cognition Disorders; Cre | 2007 |
Executive function is associated with brain proton magnetic resonance spectroscopy in amnestic mild cognitive impairment.
Topics: Aged; Amnesia; Analysis of Variance; Cognition Disorders; Creatine; Female; Gyrus Cinguli; Humans; I | 2007 |
Cortical brain metabolism as measured by proton spectroscopy is related to memory performance in patients with amnestic mild cognitive impairment and Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Amnesia; Aspartic Acid; Cerebral Cortex; Cognition Disorders; Creatine; Fem | 2007 |
1H MRS allows brain phenotype differentiation in sisters with late onset ornithine transcarbamylase deficiency (OTCD) and discordant clinical presentations.
Topics: Adult; Age of Onset; Brain; Brain Chemistry; Cell Differentiation; Cognition Disorders; Female; Huma | 2008 |
Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease.
Topics: Adolescent; Adult; Aspartic Acid; Atrophy; Brain; Cerebral Ventricles; Cognition Disorders; Cohort S | 2008 |
Correlation between cognitive status and cerebral inositol in Alzheimer-type dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Case-Control Studies; Cognition Disorders; Female | 1998 |
Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Mapping; Choline; Cognition Disorde | 2000 |
Metabolic and cognitive response to human traumatic brain injury: a quantitative proton magnetic resonance study.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Brain Injuries; Choline; Cognition Disorders; Creatinine; Cr | 2000 |
Correlation of cerebral metabolites with clinical outcome among patients with severe congestive heart failure.
Topics: Aspartic Acid; Brain; Choline; Cognition Disorders; Creatine; Disease Progression; Heart Failure; Hu | 2001 |
(1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Choline; Cognitio | 2001 |
Elevated myo-inositol concentrations in cerebrospinal fluid of neonates and of patients with an impaired state of consciousness.
Topics: Adolescent; Adult; Age Factors; Aged; Blood-Brain Barrier; Central Nervous System Diseases; Child; C | 1976 |